Annals of hematology · 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakamura Naokazu, Arima Nobuyoshi, Takakuwa Teruhito, Yoshioka Satoshi, Imada Kazunori, Fukushima Kentaro, Hotta Masaaki, Fuchida Shin-Ichi, Kanda Junya, Uoshima Nobuhiko, Shimura Yuji, Tanaka Hirokazu, Ohta Kensuke, Kosugi Satoru, Yagi Hideo, Yoshihara Satoshi, Yamamura Ryosuke, Adachi Yoko, Hanamoto Hitoshi, Shibayama Hirohiko, Hosen Naoki, Ito Tomoki, Shimazaki Chihiro, Takaori-Kondo Akifumi, Kuroda Junya, Matsumura Itaru, Hino Masayuki, Kansai Myeloma Forum
Аннотация
Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.